The first part of the verification of the expressions of interest of our Members who have requested the inclusion of their Chinese and expat employees of the branches in China in the priority list for BNT vaccinations against Covid-19 has been concluded. available to members and directors of the Foundation thanks to the collaboration with the partner and director Fosun, through its arm Fosun Pharma.
Currently, inquiries have been received for around 4,000 doses from a significant number of China-based associates. It is still possible to indicate your interest in being included in the list. It will be our responsibility to point out the interest to Fosun and encourage direct contact for the subsequent operational steps.
To take advantage of the opportunity, you need to write an email to Alessandra Sartoretti (email@example.com), including the following information:
- Company name in China
- Headquarters / locations (province, city)
- Indicative number of doses needed
The Italy China Foundation is currently monitoring the process pending information on the next steps, on which our members will be constantly informed, in favor of whom the initiative has been deliberately organized.
We remind you that in these weeks it is possible to renew the association, for information you can contact our Secretariat for Associative Relations at firstname.lastname@example.org.
Information about the project
Fosun Pharma has the exclusive distribution right in Greater China and has provided important clinical resources for the BNT vaccine in the early stage of research and development. If a company is interested in the vaccine for its Chinese employees, it will be necessary to contact Fosun directly. In the event that the request exceeds one thousand units, it will be necessary to sign a letter of intent to plan the pre-orders and give priority to that company. Priority planning will still be coordinated for centralized vaccination needs, given that vaccines have production limitations in their initial phase.
Fosun Pharma has started a deep collaboration with BioNTech Germany since March 2020 in clinical research, product registration and vaccine product development focused on COVID-19 mRNA technology in the Greater China region (including Hong Kong, Taiwan and Macau). On November 18, BioNTech / Pfizer released final data from the Phase III clinical trial: 95% overall effective rate and 94% effective rate for people over the age of 65. On November 20, BioNTech / Pfizer filed an Emergency Use Authorization (EUA) application with the FDA in addition to the other applications in sequence to drug regulatory agencies in Australia, Canada, the European Union, Japan and the United Kingdom.